This multi-center, multi-country retrospective cohort study will assess the clinical course and outcome of adults with severe COVID-19 not treated with remdesivir using a 7-point ordinal scale for clinical outcomes on Day 14 and all-cause mortality at Day 28 after admission. This study complements ongoing clinical trials of remdesivir for the treatment of severe COVID-19 infection.